201 related articles for article (PubMed ID: 16006888)
1. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Arlen PM; Gulley JL; Todd N; Lieberman R; Steinberg SM; Morin S; Bastian A; Marte J; Tsang KY; Beetham P; Grosenbach DW; Schlom J; Dahut W
J Urol; 2005 Aug; 174(2):539-46. PubMed ID: 16006888
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
4. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
5. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
[TBL] [Abstract][Full Text] [Related]
7. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
8. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
9. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
[TBL] [Abstract][Full Text] [Related]
10. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
13. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
Malone S; Perry G; Segal R; Dahrouge S; Crook J
BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.
North SA; Graham K; Bodnar D; Venner P
J Urol; 2006 Jul; 176(1):91-5. PubMed ID: 16753376
[TBL] [Abstract][Full Text] [Related]
15. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
17. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Urol; 2005 May; 173(5):1572-6. PubMed ID: 15821488
[TBL] [Abstract][Full Text] [Related]
18. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Madan RA; Gulley JL; Schlom J; Steinberg SM; Liewehr DJ; Dahut WL; Arlen PM
Clin Cancer Res; 2008 Jul; 14(14):4526-31. PubMed ID: 18628467
[TBL] [Abstract][Full Text] [Related]
19. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
20. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
